The European Medicines Agency granted Strekin’s STR001 orphan drug status for the treatment of hearing loss.

STR001 is a peroxisome-proliferator-activated receptor- gamma agonist, currently being investigated in a Phase II clinical trial. The product protects the sensory hair cells of the inner ear by various mechanisms of action.

Results from the ongoing trial are expected in the fourth quarter of this year.